nonprofit logo

Oxfendazole Development Group

Learn about this cause: Is it Legit? Do I like the mission? What is the CEO's salary?

EIN: 811547477 ✦ Blue bell, PA ✦ Designated as a 501(c)(3)

Overview

What is Oxfendazole Development Group?

The Oxfendazole Development Group is a 501c3 nonprofit organization located at 736 Cathcart Rd, Blue Bell, PA 19422. Their primary mission is to conduct research and development for the creation of pharmaceutical treatments aimed at eliminating neglected tropical diseases (NTDs), with a particular focus on oxfendazole. Their nonclinical work and clinical studies aim to improve our understanding of various aspects related to oxfendazole, such as its interactions with other medications, effects on transporters and enzymes, and its stability in different species. These investigations contribute to the development of more effective treatments for individuals in need.


Official website here: www.https: oxfendazoledevelopmentgroup.org

Is Oxfendazole Development Group legitimate?

Oxfendazole Development Group is a legitimate nonprofit organization registered as a 501(c)(3) entity. Oxfendazole Development Group submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.

Here are some key statistics you may want to consider:

Executive Compensation: $0
Professional Fundraising Fees: $0
Other Salaries and Wages: $0

For more financial information, click here


Official website here: www.https: oxfendazoledevelopmentgroup.org

What is the mission statement of Oxfendazole Development Group?

The Oxfendazole Development Group, a 501c3 nonprofit organization, is dedicated to charitable purposes, focusing primarily on research and development of pharmaceutical treatments to combat neglected tropical diseases (NTDs), particularly oxfendazole. Their mission is to facilitate access to these treatments for individuals in need, by conducting nonclinical work and clinical studies. The organization has undertaken studies to enhance understanding of oxfendazole's interactions with other medicines, its effects on transporters, enzymes responsible for metabolism, and its stability in various species. The research also includes examining oxfendazole metabolites obtained through incubation with hepatocytes of various species.


Official website here: www.https: oxfendazoledevelopmentgroup.org

What is the revenue of Oxfendazole Development Group?

Oxfendazole Development Group's revenue in 2022 was $1,710,127.


Official website here: www.https: oxfendazoledevelopmentgroup.org

Who are the executives of Oxfendazole Development Group and what are their salaries?

Here are 5 key members and their salaries:

    Hector Hugo Garcia (President Board Member) [Trustee/Director]
  • Compensation: $0
  • Related: $0
  • Other: $0

    • R John Horton (Secretary Board Member) [Trustee/Director]
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Ellen Codd (Treasurer Board Member) [Trustee/Director]
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Robert H Gilman (Board Member) [Trustee/Director]
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Armando Gonzalez (Board Member) [Trustee/Director]
  • Compensation: $0
  • Related: $0
  • Other: $0


  • Official website here: www.https: oxfendazoledevelopmentgroup.org

    Where can I find the form 990 for Oxfendazole Development Group?

    The Oxfendazole Development Group’s most recent form 990 was submitted in 2022 and can be accessed here


    Official website here: www.https: oxfendazoledevelopmentgroup.org

    Learn more at the official website: www.https: oxfendazoledevelopmentgroup.org

    Mission Statement of Oxfendazole Development Group

    The Oxfendazole Development Group, a 501c3 organization, was established with a mission to contribute to charitable purposes, specifically focusing on research and development of pharmaceutical treatments to combat neglected tropical diseases (NTDs). With a particular interest in oxfendazole, the group aims to eliminate these diseases and ensure access to these treatments for those in need. To achieve this mission, the organization engages in nonclinical work and conducts clinical studies to enhance our understanding of various aspects related to oxfendazole, such as its interactions with other medicines, effects on transporters and enzymes, stability in different species, and metabolites obtained through incubation with hepatocytes from various species. By conducting these studies, the Oxfendazole Development Group plays a crucial role in advancing the development of effective treatments against neglected tropical diseases, ultimately contributing to improved health and well-being for affected individuals worldwide.

    Impact

    This information is meant to be a general summary of Oxfendazole Development Group. Please take the time to review official sources before making any decisions based upon the content provided here.




    Saturday, July 20, 2024

    The Oxfendazole Development Group's impact lies in its significant contributions to medical research focused on eliminating neglected tropical diseases, particularly through the study and advancement of oxfendazole treatments. Their activities include conducting nonclinical work and clinical studies to better understand the potential interactions of oxfendazole with other medicines, its effects on transporters and enzymes responsible for metabolism, as well as its stability across different species. Their dedication to this cause is evident in their mission of advancing pharmaceutical treatments to combat NTDs and improving access to these treatments for those in need.





    Financials

    This financial information is from Propublica.

    Revenue
    Expenses
    Efficiency

    Other financial information:

    This information is from the most recently submitted tax form from this organization, which was in 2022.

  • Investment Income: $7,108
  • Program Service Revenue: $0
  • Gross Receipts: $1,710,127

    • Assets and Liabilities:
  • Total Assets: $1,721,909
  • Total Liabilities: $17,527
  • Net Assets: $1,704,382
  • Organization Details

    Founding Year

    2016

    Main Address

    736 CATHCART RD, BLUE BELL, PA, 194221411

    NTEE Category

    Code: H80 - Medical research

    If you are a representative of Oxfendazole Development Group and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.